Company Profile
COMPASS Pathways Plc Stock Price, News & Catalysts
- Ticker:
- CMPS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
14.20 USD (+6.53%)
Close
Last updated: August 24, 2026
1.8B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, CMPS closed up 6.53% at $14.20. No new same-company headline was identified in the current news window.
Company overview
Business overview
COMPASS Pathways is a neuroscience company focused on psychedelic-assisted therapy and depression. Its story is centered on whether a novel mental-health paradigm can be translated into regulated medicine.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and listed on NASDAQ as an ADR, COMPASS sits in specialty neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical data, regulatory progress, and the commercial viability of a new treatment model for depression.
Position Within the Biotechnology Landscape
COMPASS is a high-catalyst CNS name whose value is heavily tied to clinical and regulatory outcomes.
Future catalysts
- Compass Pathways’s key catalyst is COMP360 in treatment-resistant depression, with the next clinical and regulatory steps doing most of the work. The market will react quickly if the psilocybin story keeps building toward a viable commercial path.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of COMPASS Pathways Plc (CMPS)?
COMPASS Pathways Plc (CMPS) most recently closed at 14.20 USD, a +6.53% move versus the previous session.
What is the market cap of COMPASS Pathways Plc (CMPS)?
COMPASS Pathways Plc currently has a market capitalization of 1.8B USD on BioPharmSignal.
What does COMPASS Pathways Plc do?
COMPASS Pathways is a neuroscience company focused on psychedelic-assisted therapy and depression. Its story is centered on whether a novel mental-health paradigm can be translated into regulated medicine.
On which exchange is CMPS stock listed?
COMPASS Pathways Plc (CMPS) is associated with NASDAQ, United Kingdom, Biopharma.
What is Pathways?
Compass Pathways’s key catalyst is COMP360 in treatment-resistant depression, with the next clinical and regulatory steps doing most of the work.
Which conditions is COMPASS Pathways Plc targeting with Pathways?
COMPASS Pathways Plc is associated with neuroscience based on its company overview and current catalyst commentary.
How does COMPASS Pathways Plc describe recent progress with Pathways?
Compass Pathways’s key catalyst is COMP360 in treatment-resistant depression, with the next clinical and regulatory steps doing most of the work.
What is Compass?
COMPASS Pathways is a neuroscience company focused on psychedelic-assisted therapy and depression.